Hjem › Diffust stort B-celle lymfom › Louisiana
Diffust stort B-celle lymfom kliniske forsøg i Louisiana
6 studier for Diffust stort B-celle lymfom søger deltagere på steder i Louisiana.
Byer i Louisiana
Officiel studietekst (engelsk)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mary Bird Perkins Cancer Center, Baton Rouge
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05006716A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care ( Site 0184), Alexandria
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06717347A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Our Lady of the Lake Physician Group-Medical Oncology ( Site 0180), Baton Rouge
- Ochsner LSU Health - Monroe Medical Center, Family Medicine Clinic ( Site 0209), Monroe
- Ochsner Clinic Foundation ( Site 0189), New Orleans
- og 1 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06890884Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Mary Bird Perkins Cancer Ctr, Baton Rouge
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06806033Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Louisiana State University Health Sciences Center, Shreveport
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT05826535DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Tulane Cancer Center Office of Clinical Research, New Orleans
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 7. apr. 2023 · NCT04920617Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.